Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study
Authors:
- 18 October 2010
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (1) , 65-74
Abstract
Aim: To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase‐4 (DPP‐4) inhibitor linagliptin administered as add‐on therapy to metformin in patients with type 2 diabetes with inadequate glycaemic control. Methods: This 24‐week, randomized, placebo‐controlled, double‐blind, parallel‐group study was carried out in 82 centres in 10 countries. Patients with HbA1c levels of 7.0–10.0% on metformin and a maximum of one additional antidiabetes medication, which was discontinued at screening, continued on metformin ≥1500 mg/day for 6 weeks, including a placebo run‐in period of 2 weeks, before being randomized to linagliptin 5 mg once daily (n = 524) or placebo (n = 177) add‐on. The primary outcome was the change from baseline in HbA1c after 24 weeks of treatment, evaluated with an analysis of covariance (ANCOVA). Results: Mean baseline HbA1c and fasting plasma glucose (FPG) were 8.1% and 9.4 mmol/l, respectively. Linagliptin showed significant reductions vs. placebo in adjusted mean changes from baseline of HbA1c (−0.49 vs. 0.15%), FPG (−0.59 vs. 0.58 mmol/l) and 2hPPG (−2.7 vs. 1.0 mmol/l); all p < 0.0001. Hypoglycaemia was rare, occurring in three patients (0.6%) treated with linagliptin and five patients (2.8%) in the placebo group. Body weight did not change significantly from baseline in both groups (−0.5 kg placebo, −0.4 kg linagliptin). Conclusions: The addition of linagliptin 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin resulted in a significant and clinically meaningful improvement in glycaemic control without weight gain or increased risk of hypoglycaemia.Keywords
This publication has 33 references indexed in Scilit:
- Mortality attributable to diabetes: Estimates for the year 2010Diabetes Research and Clinical Practice, 2010
- Global estimates of the prevalence of diabetes for 2010 and 2030Diabetes Research and Clinical Practice, 2010
- Novel Approaches to the Treatment of Type 2 DiabetesJournal of Pharmacy Practice, 2009
- Standards of Medical Care in Diabetes—2009Diabetes Care, 2009
- Gliptins: a new class of oral hypoglycaemic agentQJM: An International Journal of Medicine, 2007
- Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus2007
- Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigmInternational Journal Of Clinical Practice, 2007
- Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetesCurrent Medical Research and Opinion, 2007
- Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetesDiabetes & Vascular Disease Research, 2006
- Timely Addition of Insulin to Oral Therapy for Type 2 DiabetesDiabetes Care, 2002